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Dear Editor, 
Obinutuzumab is a humanized anti-CD20 monoclonal antibody that is currently recommended in 
combination with chlorambucil for first-line treatment of chronic-lymphocytic-leukemia (CLL) in 
patients unfit for fludarabine-based therapy. Although shown to be superior than rituximab in this 
setting [1], safety profile of obinutuzumab is not as well established. Progressive-multifocal-
leukoencephalopathy (PML) is a severe, fatal, demyelinating disease of central-nervous-system (CNS) 
caused by reactivation of John-Cunningham (JC) virus. Although very rare, it is associated with 
exposure to immunosuppressive agents like rituximab and other monoclonal antibodies. Only three 
PML cases have been reported in association with obinutuzumab exposure, but all of them were 
confounded with prior rituximab therapy [2]. Here we report the first documented case of PML 
developing after exposure to obinutuzumab in a treatment-naïve patient treated for CLL.  
A 62-year-old female patient was diagnosed with CLL in 2005. Her medical history included 
tuberculosis of left tibia in the childhood, pulmonary emphysema and recurrent pneumonias, but no 
previous neurological disorders. Due to CLL progression and presence of comorbidities, she started 
obinutuzumab and chlorambucil in 10/2017 and received total of 6 cycles ending in 4/2018, achieving 
complete remission. She had no chronic therapy for previous conditions and was concomitantly 
treated with alopurinol and ranitidine. In 5/2018 she started complaining of progressively worsening 
blurred vision. Ophthalmologic examination did not identify the cause, but the CT and subsequent 
magnetic-resonance T2-weighted-images showed hyperintensive subcortical lesions (Figure), initially 
indicative of posterior-reversible-encephalopathy-syndrome (PRES). However, further radiologic 
progression of brain lesions, lack of clinical improvement and confirmation of JC virus by polymerase-
chain-reaction in the cerebrospinal-fluid defined the diagnosis of PML. Despite radiologic progression 
of brain lesions, patient exhibited stable clinical course with only visual impairment for 5 months after 
first symptoms, but then rapid cognitive and neurologic deterioration occurred. Course of 
intravenous-immunoglobulins was instituted, but with no clinical benefit. Patient remains alive, but 
seriously disabled, unable to care for herself with tendency for further deterioration at the time of 
this report, now 6 months after first occurrence of neurological symptoms.  
PML is a serious demyelinating disease of CNS with no effective treatment available and almost always 
fatal outcome. Although limited number of PML cases in association with obinutuzumab have been 
reported in the literature, all of these patients were exposed to prior rituximab therapy, thereby 
confounding the possible role of obinutuzumab as an incriminated agent. Our case clearly 
demonstrates that association between obinutuzumab and PML exists and undoubtedly confirms the 
safety precaution from the drug-label. Obinutuzumab is more potent in terms of B-cell depletion than 
rituximab [3] and it is expected to be increasingly used in the treatment of CLL and indolent B-cell 
lymphomas. Our case underlies the fact that the current incidence of PML during obinutuzumab 
treatment is unknown and further investigations regarding exposure to obinutuzumab, as well as 
number of incident cases associated with exposure are needed to clearly establish safety of such 
potent therapy. Question arises, whether PML-risk-management-strategies, such as used in the case 
of natalizumab [4], should be undertaken in obinutuzumab candidates as well.  
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Figure: Patient presented with bilateral occipital and right periinsular subcortical lesions. A) Initial T2 
weighted magnetic resonance (MR) brain image (6/2018) showing hyperintensive subcortical lesions 
bilaterally occipitally. B) Progression of occipital lesions was observed on follow-up MR images 
(10/2018).
 
 
